Albertioni F, Herngren L, Juliusson G, Liliemark J
Department of Clinical Pharmacology, Karolinska Hospital, Stockholm, Sweden.
Eur J Clin Pharmacol. 1994;46(6):563-4. doi: 10.1007/BF00196117.
The plasma protein binding of 2-chloro-2'-deoxyadenosine (CdA) at 37 degrees C was studied by ultrafiltration in 5 healthy volunteers, in 11 patients with haematological malignancies and in purified protein preparations. In the patients, the binding of CdA to plasma proteins was 25.0% and in healthy subjects it was 21.1%. In a solution of human serum albumin (40 g.l-1), 24.3% CdA was bound, but less than 5% was bound in a solution of alpha 1-acid-glycoprotein (0.7 g.l-1). No dependence of binding on the concentration of CdA was found within a range 25-1000 nmol.l-1. In conclusion, due to its limited binding to plasma proteins, any change in the binding of CdA is unlikely to have a major influence on its pharmacological effect.
通过超滤法，在5名健康志愿者、11名血液系统恶性肿瘤患者以及纯化蛋白制剂中研究了2-氯-2'-脱氧腺苷（CdA）在37℃时与血浆蛋白的结合情况。在患者中，CdA与血浆蛋白的结合率为25.0%，在健康受试者中为21.1%。在人血清白蛋白溶液（40 g·l⁻¹）中，24.3%的CdA被结合，但在α1-酸性糖蛋白溶液（0.7 g·l⁻¹）中，结合率不到5%。在25 - 1000 nmol·l⁻¹范围内，未发现结合情况与CdA浓度有关。总之，由于CdA与血浆蛋白的结合有限，其结合情况的任何变化都不太可能对其药理作用产生重大影响。
